Deutsche Bank Sees Achillion, Arrowhead As Potential Takeover Targets
"If you want to compete with Gilead, you have to buy Achillion," Deutsche Bank's Robyn Karnauskas said on CNBC. "We think that's one take-out target."
Karnauskas noted Achillion's pipeline has promising treatments for hepatitis.
A similar appraisal of Achillion came Monday from UBS's Andrew Peters, who highlighted "a scarcity of de-risked assets."
Speculation about the acquisition of development-stage drug companies has been rife after InterMune (NASDAQ: ITMN) agreed to an $8.3 billion buyout by Roche on Sunday.
Kanauskas appearing on CNBC's "Fast Money" program Monday evening, also said Arrowhead Research "may be attractive" if it releases positive data for its hepatitis drug later this autumn,
Achillion traded recently at $11.65, up eight percent; Arrowhead traded at $15.13, up 12.6 percent.
Latest Ratings for ACHN
|Nov 2016||Chardan Capital||Upgrades||Sell||Neutral|
|Sep 2016||Wedbush||Initiates Coverage on||Outperform|
|Sep 2016||FBR Capital||Initiates Coverage on||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.